653 results on '"Tramontano, Enzo"'
Search Results
202. Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines
- Author
-
Mai, Antonello, Artico, Marino, Sbardella, Gianluca, Massa, Silvio, Loi, Anna Giulia, Tramontano, Enzo, Scano, Patrizia, and La Colla, Paolo
- Subjects
Nonnucleoside Inhibitors ,HIV-1 Replication ,Magnetic Resonance Spectroscopy ,Human-Immunodeficiency-Virus ,DABOs ,Antiviral Agents ,Cell Line ,Reverse-Transcriptase Inhibitors ,AIDS ,Structure-Activity Relationship ,Pyrimidines ,Cytopathogenic Effect, Viral ,HIV-1 ,Humans - Abstract
Various thio analogues of dihydroalkoxybenzyloxopyrimidines (DABOs), a new class of non-nucleoside reverse transcriptase inhibitors, were found to selectively inhibit the HIV-1 multiplication in vitro. Among the C-5 H-substituted 6-benzyl-3,4-dihydro-4-oxopyrimidines, the introduction of alkylthio or cycloalkylthio substituents at C-2 of the pyrimidine ring led to derivatives (S-DABOs) which were up to 10-fold more potent than the alkyloxy or cycloalkyloxy counterparts. The further introduction of a methyl group at the 3'-position of the benzyl portion of 2-(alkylthio)-6-benzyluracils reduced the cytotoxicity leading to more selective compounds. Among C-5 methyl-substituted S-DABOs, numerous derivatives showed EC50 values as low as 0.6 microM and lacked cytotoxicity at doses as high as 300 microM. In the C-5 double methyl-substituted series, a more pronounced cytotoxicity was observed and the further introduction of a methyl at the 3'-position in the benzylidene group resulted in total loss of antiviral activity. S-DABOs, namely 2-(alkylthio)-6-benzyl-3,4-dihydro-4-oxopyrimidines, were synthesized by reacting proper methyl (phenylacetyl)acetates or their 2-methyl compounds with thiourea to afford 6-benzyl-4-oxo-1,2,3,4-tetrahydro-2-thiaoxopyrimidines or the related 5-methyl derivatives. Treatment of the latter derivatives with alkyl or cycloalkyl halides in alkaline medium gave the required title compounds.
- Published
- 1995
203. Inhibition of HIV-1 reverse transcriptase associated activities by the hydroalcoholic extract of Casimiroa edulis seeds
- Author
-
Esposito, Francesca, primary, Zinzula, Luca, additional, Maxia, Andrea, additional, Tramontano, Enzo, additional, and Sanna, Cinzia, additional
- Published
- 2011
- Full Text
- View/download PDF
204. Identification of HIV-1 Reverse Transcriptase Dual Inhibitors by a Combined Shape-, 2D-Fingerprint- and Pharmacophore-based Virtual Screening Approach
- Author
-
Distinto, Simona, primary, Esposito, Francesca, additional, Kirchmair, Johannes, additional, Cardia, Cristina M., additional, Maccioni, Elias, additional, Alcaro, Stefano, additional, Zinzula, Luca, additional, and Tramontano, Enzo, additional
- Published
- 2011
- Full Text
- View/download PDF
205. Design and Synthesis of New Isatin Derivatives as HIV-1 Reverse Transcriptase Associated Ribonuclease H Inhibitors
- Author
-
Esposito, Francesca, primary, Meleddu, Rita, additional, Sanna, Maria Luisa, additional, Distinto, Simona, additional, Corona, Angela, additional, Cannas, Valeria, additional, Tramontano, Enzo, additional, and Cardia, Maria Cristina, additional
- Published
- 2011
- Full Text
- View/download PDF
206. dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35
- Author
-
Zinzula, Luca, primary, Esposito, Francesca, additional, Pala, Daniela, additional, and Tramontano, Enzo, additional
- Published
- 2011
- Full Text
- View/download PDF
207. Preparation of 6-benzyl-4-oxopyrimidines as antiviral agents
- Author
-
Artico, Marino, Massa, Silvio, Mai, Antonello, La Colla, Paolo, Marongiu, Maria Elena, and Tramontano, Enzo.
- Subjects
antiviral agents - Published
- 1994
208. DABOs: A New Class of Non-Nucleoside Reverse Transcriptase Inhibitors
- Author
-
Tramontano, Enzo, Loi, Anna Giulia, De Montis, Antonella, Marongiu, Maria Elena, Scano, Patrizia, La Colla, Paolo, Artico, Marino, Massa, Silvio, Mai, Antonello, and Sbardella, Gianluca
- Published
- 1994
209. Purification and functional characterization of the full length recombinant Ebola virus VP35 protein expressed in E. coli
- Author
-
Zinzula, Luca, primary, Esposito, Francesca, additional, Mühlberger, Elke, additional, Trunschke, Martina, additional, Conrad, Dominik, additional, Piano, Dario, additional, and Tramontano, Enzo, additional
- Published
- 2009
- Full Text
- View/download PDF
210. HIV-1-Inhibiting Activity of the Essential Oil ofRidolfia segetumandOenanthe crocata
- Author
-
Bicchi, Carlo, primary, Rubiolo, Patrizia, additional, Ballero, Mauro, additional, Sanna, Cinzia, additional, Matteodo, Maura, additional, Esposito, Francesca, additional, Zinzula, Luca, additional, and Tramontano, Enzo, additional
- Published
- 2009
- Full Text
- View/download PDF
211. The Exploding Field of the HCV Polymerase Non-Nucleoside Inhibitors: Summary of a First Generation Compounds
- Author
-
Tramontano, Enzo, primary
- Published
- 2008
- Full Text
- View/download PDF
212. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587
- Author
-
Tramontano Enzo and Cheng Yung-Chi
- Subjects
Phosphonoacetic Acid ,Stereochemistry ,DNA polymerase ,Pyridines ,Biochemistry ,Antiviral Agents ,chemistry.chemical_compound ,Nevirapine ,Polymerase ,Pharmacology ,chemistry.chemical_classification ,biology ,Active site ,Templates, Genetic ,Reverse transcriptase ,Enzyme assay ,Kinetics ,Enzyme ,chemistry ,Enzyme inhibitor ,biology.protein ,HIV-1 ,Reverse Transcriptase Inhibitors ,Zidovudine ,DNA ,Foscarnet - Abstract
The dipyridodiazepinone derivative 6,11-dihydro-11-cyclopropyl-4-methyldipyrido[2,3- b :2',3'- e ]-[1,4]diazepin-6-one (BI-RG-587) selectively inhibits human immunodeficiency virus type 1 (HIV-1) replication by suppressing HIV-1 reverse transcriptase activity. Both RNA- and DNA-dependent polymerase associated activities of this enzyme were found to be inhibited by BI-RG-587 in a pattern dependent on the template used. The lowest ic 50 values were obtained using poly(rC)-oligo (dG) 12–18 and poly(dA)-oligo(dT) 12–18 as template-primer. For the RNA-dependent activity poly (rC)-oligo(dG) 12–18 and dGTP appeared to enhance the inhibition of the RNA-dependent enzyme activity by BI-RG-587, with the effect of poly(rC)-oligo(dG) 12–18 dominating that of dGTP. Poly(rA)-oligo (dT) 10 seemed to decrease the inhibition whereas poly(rU)-oligo(dA) 12–18 or poly(rG)-oligo-(dC) 12–18 had no effect. dATP, dTTP and dCTP, three nucleotide triphosphates, also had no impact on the inhibition. Differences were observed for the template-dependent action of BI-RG-587 against the DNA-dependent enzyme activity. Both substrates were required to allow the inhibition by BI-RG-587 in the poly(dC)-oligo(dG) 12–18 and dGTP reaction, whereas only the template and enzyme interaction seemed to be necessary for the poly(dA)-oligo(dT) 12–18 and dTTP reaction. The different behaviors of DNA- and RNA-dependent DNA polymerase activities could indicate either the presence of different active sites for distinct activities or the presence of a unique active site with different configurations depending upon the template used. Also, BI-RG-587 showed a mutually exclusive inhibition when combined with two other classes of HIV-1 RT inhibitors represented by phosphonoformic acid and 3'-azido-3'-dideoxythymidine triphosphate.
- Published
- 1992
213. An Efficient Route to Novel Uracil-Based Drug-Like Molecules.
- Author
-
Babkov, Denis A., Chizhov, Alexander O., Khandazhinskaya, Anastasia L., Corona, Angela, Esposito, Francesca, Tramontano, Enzo, Seley-Radtke, Katherine L., and Novikov, Mikhail S.
- Subjects
URACIL derivatives ,CHEMICAL reactions ,GRIGNARD reagents ,AMIDES ,ANTIRETROVIRAL agents ,BENZOPHENONES - Abstract
In order to identify new antiretroviral agents, a series of novel uracil derivatives have been synthesized. Optimized conditions for coupling of Weinreb amides with aromatic Grignard reagents allow the convenient preparation of key benzophenone intermediates in high yields and purities. The use of a modified silyl Hilbert-Johnson reaction affords the target compounds under mild conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
214. Structure–ActivityRelationship of PyrrolylDiketo Acid Derivatives as Dual Inhibitors of HIV-1 Integraseand Reverse Transcriptase Ribonuclease H Domain.
- Author
-
Cuzzucoli Crucitti, Giuliana, Métifiot, Mathieu, Pescatori, Luca, Messore, Antonella, Madia, Valentina Noemi, Pupo, Giovanni, Saccoliti, Francesco, Scipione, Luigi, Tortorella, Silvano, Esposito, Francesca, Corona, Angela, Cadeddu, Marta, Marchand, Christophe, Pommier, Yves, Tramontano, Enzo, Costi, Roberta, and Di Santo, Roberto
- Published
- 2015
- Full Text
- View/download PDF
215. HIV-1 RNase H: Recent Progress in an Exciting, yet Little Explored, Drug Target
- Author
-
Tramontano, Enzo, primary
- Published
- 2006
- Full Text
- View/download PDF
216. 6-Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays
- Author
-
Costi, Roberta, primary, Santo, Roberto Di, additional, Artico, Marino, additional, Roux, Alessandra, additional, Ragno, Rino, additional, Massa, Silvio, additional, Tramontano, Enzo, additional, La Colla, Massimiliano, additional, Loddo, Roberta, additional, Marongiu, M.Elena, additional, Pani, Alessandra, additional, and Colla, Paolo La, additional
- Published
- 2004
- Full Text
- View/download PDF
217. New Anti-Human Immunodeficiency Virus Type 1 6-Aminoquinolones: Mechanism of Action
- Author
-
Parolin, Cristina, primary, Gatto, Barbara, additional, Del Vecchio, Claudia, additional, Pecere, Teresa, additional, Tramontano, Enzo, additional, Cecchetti, Violetta, additional, Fravolini, Arnaldo, additional, Masiero, Sara, additional, Palumbo, Manlio, additional, and Palù, Giorgio, additional
- Published
- 2003
- Full Text
- View/download PDF
218. Antitumor Agents. 1. Synthesis, Biological Evaluation, and Molecular Modeling of 5H-Pyrido[3,2-a]phenoxazin-5-one, a Compound with Potent Antiproliferative Activity
- Author
-
Bolognese, Adele, primary, Correale, Gaetano, additional, Manfra, Michele, additional, Lavecchia, Antonio, additional, Mazzoni, Orazio, additional, Novellino, Ettore, additional, Barone, Vincenzo, additional, Pani, Alessandra, additional, Tramontano, Enzo, additional, La Colla, Paolo, additional, Murgioni, Chiara, additional, Serra, Ilaria, additional, Setzu, Giovanna, additional, and Loddo, Roberta, additional
- Published
- 2002
- Full Text
- View/download PDF
219. 6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoicAcids as Dual Inhibitors of Recombinant HIV-1 Integrase andRibonuclease H, Synthesized by a Parallel Synthesis Approach.
- Author
-
Costi, Roberta, MeÌtifiot, Mathieu, Esposito, Francesca, Cuzzucoli Crucitti, Giuliana, Pescatori, Luca, Messore, Antonella, Scipione, Luigi, Tortorella, Silvano, Zinzula, Luca, Novellino, Ettore, Pommier, Yves, Tramontano, Enzo, Marchand, Christophe, and Di Santo, Roberto
- Published
- 2013
- Full Text
- View/download PDF
220. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives
- Author
-
Mai, Antonello, primary, Artico, Marino, additional, Sbardella, Gianluca, additional, Massa, Silvio, additional, Novellino, Ettore, additional, Greco, Giovanni, additional, Loi, Anna Giulia, additional, Tramontano, Enzo, additional, Marongiu, Maria Elena, additional, and La Colla, Paolo, additional
- Published
- 1999
- Full Text
- View/download PDF
221. Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate
- Author
-
Tramontano, Enzo, primary, Piras, Giovanna, additional, Mellors, John W, additional, Putzolu, Monica, additional, Bazmi, Hengameh Z, additional, and Colla, Paolo La, additional
- Published
- 1998
- Full Text
- View/download PDF
222. Geometrically and Conformationally Restrained Cinnamoyl Compounds as Inhibitors of HIV-1 Integrase: Synthesis, Biological Evaluation, and Molecular Modeling
- Author
-
Artico, Marino, primary, Di Santo, Roberto, additional, Costi, Roberta, additional, Novellino, Ettore, additional, Greco, Giovanni, additional, Massa, Silvio, additional, Tramontano, Enzo, additional, Marongiu, Maria E., additional, De Montis, Antonella, additional, and La Colla, Paolo, additional
- Published
- 1998
- Full Text
- View/download PDF
223. Biochemical Characterization of the HIV-1 Integrase 3‘-Processing Activity and Its Inhibition by Phosphorothioate Oligonucleotides
- Author
-
Tramontano, Enzo, primary, Colla, Paolo La, additional, and Cheng, Yung-Chi, additional
- Published
- 1998
- Full Text
- View/download PDF
224. Preparation and anti-HIV-1 activity of Thio Analogues of Dichydroalkoxybenzyloxopyrimidines
- Author
-
Mai, Antonello, primary, Artico, Marino, additional, Sbardella, Gianluca, additional, Massa, Silvio, additional, Loi, Anna Giulia, additional, Tramontano, Enzo, additional, Scano, Patrizia, additional, and La Colla, Paolo, additional
- Published
- 1995
- Full Text
- View/download PDF
225. Proceedings of the Frontiers of Retrovirology Conference 2016
- Author
-
Zurnic, Irena, Hütter, Sylvia, Lehmann, Ute, Stanke, Nicole, Reh, Juliane, Kern, Tobias, Lindel, Fabian, Gerresheim, Gesche, Hamann, Martin, Müllers, Erik, Lesbats, Paul, Cherepanov, Peter, Serrao, Erik, Engelman, Alan, Lindemann, Dirk, Da Silva Santos, Claire, Tartour, Kevin, Cimarelli, Andrea, Burdick, Rya, Chen, Jianbo, Sastri, Jaya, Hu, Wei-Shau, Pathak, Vinay, Keppler, Oliver T., Pradeau, Karine, Eiler, Sylvia, Levy, Nicolas, Lennon, Sarah, Cianferani, Sarah, Emiliani, Stéphane, Ruff, Marc, Parissi, Vincent, Rato, Sylvie, Rausell, Antonio, Munoz, Miguel, Telenti, Amalio, Ciuffi, Angela, Zhyvoloup, Alexander, Melamed, Anat, Anderson, Ian, Planas, Delphine, Kriston-Vizi, Janos, Ketteler, Robin, Lee, Chen- Hsuin, Merritt, Andy, Ancuta, Petronela, Bangham, Charles, Fassati, Ariberto, Rodari, Anthony, Van Driessche, Benoit, Galais, Mathilde, Delacourt, Nadége, Fauquenoy, Sylvain, Vanhulle, Caroline, Kula, Anna, Burny, Arsène, Rohr, Olivier, Van Lint, Carine, van Montfort, Thijs, van der Sluis, Renee, Speijer, Dave, Berkhout, Ben, Meng, Bo, Rutkowski, Andrzej, Berry, Neil, Dölken, Lars, Lever, Andrew, Schuster, Thomas, Asbach, Benedikt, Wagner, Ralf, Gross, Christine, Wiesmann, Veit, Kalmer, Martina, Wittenberg, Thomas, Gettemans, Jan, Thoma-Kress, Andrea K., Li, Minghua, Freed, Eric O., Liu, Shan-Lu, Müller, Janis, Münch, Jan, Sewald, Xaver, Uchil, Pradeep, Ladinsky, Mark, Beloor, Jagadish, Pi, Ruoxi, Herrmann, Christin, Motamedi, Nasim, Murooka, Thomas, Brehm, Michael, Greiner, Dale, Mempel, Thorsten, Bjorkman, Pamela, Kumar, Priti, Mothes, Walther, Joas, Simone, Parrish, Erica, Gnanadurai, Clement Wesley, Lump, Edina, Stürzel, Christina M., Parrish, Nicholas F., Sauermann, Ulrike, Töpfer, Katharina, Schultheiss, Tina, Bosinger, Steven, Silvestri, Guido, Apetrei, Cristian, Huot, Nicholas, Müller-Trutwin, Michaela, Sauter, Daniel, Hahn, Beatrice H., Stahl-Hennig, Christiane, Kirchhoff, Frank, Schumann, Gerald, Jung-Klawitter, Sabine, Fuchs, Nina V., Upton, Kyle R., Muñoz-Lopez, Martin, Shukla, Ruchi, Wang, Jichang, Garcia-Canadas, Marta, Lopez-Ruiz, Cesar, Gerhardt, Daniel J., Sebe, Attila, Grabundzija, Ivana, Gerdes, Patricia, Merkert, Sylvia, Pulgarin, Andres, Bock, Anja, Held, Ulrike, Witthuhn, Anett, Haase, Alexandra, Wolvetang, Ernst J., Martin, Ulrich, Ivics, Zoltán, Izsvák, Zsuzsanna, Garcia-Perez, J., Faulkner, Geoffrey J., Hurst, Tara, Katzourakis, Aris, Magiorkinis, Gkikas, Schott, Kerstin, Derua, Rita, Seifried, Janna, Reuter, Andreas, Schmitz, Heike, Tondera, Christiane, Brandariz-Nuñez, Alberto, Diaz-Griffero, Felipe, Janssens, Veerle, König, Renate, Baldauf, Hanna-Mari, Stegmann, Lena, Schwarz, Sarah-Marie, Trotard, Maud, Martin, Margarethe, Lenzi, Gina, Burggraf, Manja, Pan, Xiaoyu, Fregoso, Oliver I., Lim, Efrem S., Abraham, Libin, Erikson, Elina, Nguyen, Laura, Ambiel, Ina, Rutsch, Frank, Kim, Baek, Emerman, Michael, Fackler, Oliver T., Wittmann, Sabine, Behrendt, Rayk, Volkmann, Bianca, Eissmann, Kristin, Gramberg, Thomas, Bolduan, Sebastian, Koppensteiner, Herwig, Regensburg, Stefanie, Brack-Werner, Ruth, Draenert, Rika, Schindler, Michael, Ducroux, Aurélie, Xu, Shuting, Ponnurangam, Aparna, Franz, Sergej, Malassa, Angelina, Ewald, Ellen, Goffinet, Christine, Fung, Sin-Yee, Chan, Ching-Ping, Yuen, Chun-Kit, Kok, Kin-Hang, Chan, Chin-Ping, Jin, Dong-Yan, Dittmer, Ulf, Kmiec, Dorota, Iyer, Shilpa, Stürzel, Christina, Hahn, Beatrice, Ariumi, Yasuo, Yasuda-Inoue, Mariko, Kawano, Koudai, Tateishi, Satoshi, Turelli, Priscilla, Compton, Alex, Roy, Nicolas, Porrot, Françoise, Billet, Anne, Casartelli, Nicoletta, Yount, Jacob, Liang, Chen, Schwartz, Oliver, Magnus, Carsten, Reh, Lucia, Moore, Penny, Uhr, Therese, Weber, Jacqueline, Morris, Lynn, Trkola, Alexandra, Grindberg, Rashel V., Schlaepfer, Erika, Schreiber, Gideon, Simon, Viviana, Speck, Roberto F., Debyser, Zeger, Vranckx, Lenard, Demeulemeester, Jonas, Saleh, Suha, Verdin, Eric, Cereseto, Anna, Christ, Frauke, Gijsbers, Rik, Wang, Gang, Zhao, Na, Das, Atze T., Köstler, Josef, Perdiguero, Beatriz, Esteban, Mariano, Jacobs, Bertram L., Montefiori, David C., LaBranche, Celia C., Yates, Nicole L., Tomaras, Georgia D., Ferrari, Guido, Foulds, Kathryn E., Roederer, Mario, Landucci, Gary, Forthal, Donald N., Seaman, Michael S., Hawkins, Natalie, Self, Steven G., Phogat, Sanjay, Tartaglia, James, Barnett, Susan W., Burke, Brian, Cristillo, Anthony D., Ding, Song, Heeney, Jonathan L., Pantaleo, Giuseppe, Stab, Viktoria, Ensser, Armin, Tippler, Bettina, Burton, Dennis, Tenbusch, Matthias, Überla, Klaus, Alter, Galit, Lofano, Giuseppe, Dugast, Anne-Sophie, Kulkarni, Viraj, Suscovich, Todd, Opazo, Tatiana, Barraza, Felipe, Herrera, Diego, Garces, Andrea, Schwenke, Tomas, Tapia, Diego, Cancino, Jorge, Arriagada, Gloria, Haußner, Christina, Damm, Dominik, Rohrhofer, Anette, Schmidt, Barbara, Eichler, Jutta, Midgley, Rebecca, Wheeldon, James, Piguet, Vincent, Khopkar, Priyanka, Rohamare, Megha, Kulkarni, Smita, Godinho-Santos, Ana, Hance, Allan, Goncalves, Joao, Mammano, Fabrizio, Gasser, Romain, Hamoudi, Meriem, Pellicciotta, Martina, Zhou, Zhicheng, Visdeloup, Clara, Colin, Philippe, Braibant, Martine, Lagane, Bernard, Negroni, Matteo, Wamara, Jula, Bannert, Norbert, Mesplede, Thibault, Osman, Nathan, Anstett, Kaitlin, Liang, Jiaming Calvin, Pham, Hanh Thi, Wainberg, Mark, Shao, Wei, Shan, Jigui, Kearney, Mary, Wu, Xiaolin, Maldarelli, Frank, Mellors, John, Luke, Brian, Coffin, John, Hughes, Stephen, Fricke, Thomas, Opp, Silvana, Shepard, Caitlin, Ivanov, Dmitri, Valle-Casuso, Jose, Kanja, Marine, Cappy, Pierre, Lener, Daniela, Knyazhanskaya, Ekaterina, Anisenko, Andrey, Zatsepin, Timofey, Gottikh, Marina, Komkov, Alexander, Minervina, Anastasia, Nugmanov, Gaiaz, Nazarov, Vadim, Khodosevich, Konstantin, Mamedov, Ilgar, Lebedev, Yuri, Colomer-Lluch, Marta, Serra-Moreno, Ruth, Sarracino, Ambra, Gharu, Lavina, Pasternak, Alexander, Marcello, Alessandro, McCartin, Ann Marie, Kulkarni, Anurag, Le Douce, Valentin, Gautier, Virginie, Baeyens, Ann, Naessens, Evelien, Van Nuffel, Anouk, Weening, Karin, Reilly, Anne- Marie, Claeys, Eva, Trypsteen, Wim, Vandekerckhove, Linos, Eyckerman, Sven, Gevaert, Kris, Verhasselt, Bruno, Mok, Hoi Ping, Norton, Nicholas, Fun, Axel, Hirst, Jack, Wills, Mark, Miklik, Dalibor, Senigl, Filip, Hejnar, Jiri, Sakuragi, Jun-ichi, Sakuragi, Sayuri, Yokoyama, Masaru, Shioda, Tatsuo, Sato, Hironori, Bodem, Jochen, Moschall, Rebecca, Denk, Sarah, Erkelenz, Steffen, Schenk, Christian, Schaal, Heiner, Donhauser, Norbert, Socher, Ellen, Millen, Sebastian, Sticht, Heinrich, Mann, Melanie, Wei, Guochao, Betts, Matthew J., Liu, Yang, Kehl, Timo, Russell, Robert B., Löchelt, Martin, Hohn, Oliver, Mostafa, Saeed, Hanke, Kirsten, Norley, Stephen, Chen, Chia-Yen, Shingai, Masashi, Borrego, Pedro, Taveira, Nuno, Strebel, Klaus, Hellmund, Chris, Friedrich, Melanie, Hahn, Friedrich, Setz, Christian, Rauch, Pia, Fraedrich, Kirsten, Matthaei, Alina, Henklein, Petra, Traxdorf, Maximilian, Fossen, Torgils, Schubert, Ulrich, Khwaja, Aya, Galilee, Meytal, Alian, Akram, Schwalbe, Birco, Hauser, Heiko, Schreiber, Michael, Scherpenisse, Mirte, Cho, Young-Keol, Kim, Jungeun, Jeong, Daeun, Trejbalova, Katerina, Benesova, Martina, Kucerova, Dana, Vernerova, Zdenka, Amouroux, Rachel, Hajkova, Petra, Elleder, Daniel, Hron, Tomas, Farkasova, Helena, Padhi, Abinash, Paces, Jan, Zhu, Henan, Gifford, Robert, Murcia, Pablo, Carrozza, Maria Luisa, Niewiadomska, Anna-Maria, Mazzei, Maurizio, Abi-Said, Mounir, Hughes, Joseph, Hué, Stéphane, Obasa, Adetayo, Jacobs, Graeme, Engelbrecht, Susan, Mack, Katharina, Starz, Kathrin, Geyer, Matthias, Bibollet-Ruche, Frederic, Leoz, Marie, Plantier, Jean Christophe, Argaw-Denboba, Ayele, Balestrieri, Emanuela, Serafino, Annalucia, Bucci, Ilaria, Cipriani, Chiara, Spadafora, Corrado, Sinibaldi-Vallebona, Paolo, Matteucci, Claudia, Jayashree, S. Nandi, Neogi, Ujjwal, Chhangani, Anil K., Rathore, Shravan Sing, Mathur, Bajrang R. J., Abati, Adeyemi, Koç, B. Taylan, Oğuzoğlu, Tuba Çiğdem, Shimauchi, Takatoshi, Caucheteux, Stephan, Turpin, Jocelyn, Finsterbusch, Katja, Tokura, Yoshiki, Souriant, Shanti, Balboa, Luciana, Pingris, Karine, Kviatcowsky, Denise, Raynaud-Messina, Brigitte, Cougoule, Céline, Mercier, Ingrid, Kuroda, Marcelo, González-Montaner, Pablo, Inwentarz, Sandra, Moraña, Eduardo Jose, del Carmen Sasiain, Maria, Neyrolles, Olivier, Maridonneau-Parini, Isabelle, Lugo-Villarino, Geanncarlo, Vérollet, Christel, Herrmann, Alexandra, Thomas, Dominique, Bouzas, Nerea Ferreirós, Lahaye, Xavier, Bhargava, Anvita, Satoh, Takeshi, Gentili, Matteo, Cerboni, Silvia, Silvin, Aymeric, Conrad, Cécile, Ahmed-Belkacem, Hakim, Rodriguez, Elisa C., Guichou, Jean-François, Bosquet, Nathalie, Piel, Matthieu, Le Grand, Roger, King, Megan, Pawlotsky, Jean-Michel, Manel, Nicolas, Hofmann, Henning, Vanwalscappel, Benedicte, Bloch, Nicolin, Landau, Nathaniel, Indik, Stanislav, Hagen, Benedikt, Valle-Casuso, José Carlos, Allouch, Awatef, David, Annie, Barré-Sinoussi, Françoise, Benkirane, Monsef, Pancino, Gianfranco, Saez-Cirion, Asier, Lee, Wing-Yiu, Sloan, Richard, Schulte, Bianca, Blomberg, Jonas, Vargiu, Luana, Rodriguez-Tomé, Patricia, Tramontano, Enzo, Sperber, Göran, Kumari, Namita, Ammosova, Tatiana, Diaz, Sharmeen, Oneal, Patricia, Nekhai, Sergei, Fahrny, Audrey, Gers-Huber, Gustavo, Audigé, Annette, Jayaprakash, Anitha, Sachidanandam, Ravi, Hernandez, Matt, Dillon-White, Marsha, Maze, Emmanuel, Ham, Claire, Almond, Neil, Towers, Greg, Belshaw, Robert, de Sousa-Pereira, Patrícia, Abrantes, Joana, Pizzato, Massimo, Esteves, Pedro J., Kahle, Tanja, Schmitt, Sven, Merkel, Laura, Reuter, Nina, Stamminger, Thomas, Rosa, Ilaria Dalla, Bishop, Kate, Spinazzola, Antonella, Groom, Harriet, Vieyres, Gabrielle, Müsken, Mathias, Zillinger, Thomas, Hornung, Veit, Barchet, Winfried, Häussler, Susanne, Pietschmann, Thomas, Javed, Aneela, Leuchte, Nicole, Salinas, Gabriela, Opitz, Lennart, Sopper, Sieghart, Mummert, Christiane, Hofmann, Christian, Hückelhoven, Angela G., Bergmann, Silke, Müller-Schmucker, Sandra M., Harrer, Ellen G., Dörrie, Jan, Schaft, Niels, Harrer, Thomas, Cardinaux, Laure, Zahno, M.- L., Vogt, H.- R., Zanoni, R., Bertoni, G., Muenchhoff, Maximilian, Goulder, Philip, Keppler, Oliver, Rebensburg, Stephanie, Helfer, Markus, Zhang, Yuwei, Chen, Huicheng, Bernier, Annie, Gosselin, Annie, Routy, Jean- Pierre, Wöhrl, Birgitta, Schneider, Anna, Corona, Angela, Spöring, Imke, Jordan, Mareike, Buchholz, Bernd, Maccioni, Elias, Di Santo, Roberto, Schweimer, Kristian, Schölz, Christian, Weinert, Brian, Wagner, Sebastian, Beli, Petra, Miyake, Yasuyuki, Qi, Jun, Jensen, Lars, Streicher, Werner, McCarthy, Anna, Westwood, Nicholas, Lain, Sonia, Cox, Jürgen, Matthias, Patrick, Mann, Matthias, Bradner, James, Choudhary, Chunaram, Stern, Marcel, Valletta, Elena, Frezza, Caterina, Marino-Merlo, Francesca, Grelli, Sandro, Serafino, Anna Lucia, Mastino, Antonio, Macchi, Beatrice, Kaulfuß, Meike, Windmann, Sonja, Bayer, Wibke, Mikasi, Sello, Heß, Rebecca, Bonsmann, Michael Storcksdieck gen., Kirschning, Carsten, Lepenies, Bernd, Kolenbrander, Anne, Temchura, Vladimir, Iijima, Kenta, Kobayashi, Junya, and Ishizaka, Yukihito
- Abstract
Table of contents Oral presentations Session 1: Entry & uncoating O1 Host cell polo-like kinases (PLKs) promote early prototype foamy virus (PFV) replication Irena Zurnic, Sylvia Hütter, Ute Lehmann, Nicole Stanke, Juliane Reh, Tobias Kern, Fabian Lindel, Gesche Gerresheim, Martin Hamann, Erik Müllers, Paul Lesbats, Peter Cherepanov, Erik Serrao, Alan Engelman, Dirk Lindemann O2 A novel entry/uncoating assay reveals the presence of at least two species of viral capsids during synchronized HIV-1 infection Claire Da Silva Santos, Kevin Tartour, Andrea Cimarelli O3 Dynamics of nuclear envelope association and nuclear import of HIV-1 complexes Rya Burdick, Jianbo Chen, Jaya Sastri, Wei-Shau Hu, Vinay Pathak O4 Human papillomavirus protein E4 potently enhances the susceptibility to HIV infection Oliver T. Keppler Session 2: Reverse transcription & integration O5 Structure and function of HIV-1 integrase post translational modifications Karine Pradeau, Sylvia Eiler, Nicolas Levy, Sarah Lennon, Sarah Cianferani, Stéphane Emiliani, Marc Ruff O6 Regulation of retroviral integration by RNA polymerase II associated factors and chromatin structure Vincent Parissi Session 3: Transcription and latency O7 A novel single-cell analysis pipeline to identify specific biomarkers of HIV permissiveness Sylvie Rato, Antonio Rausell, Miguel Munoz, Amalio Telenti, Angela Ciuffi O8 A capsid-dependent integration program linking T cell activation to HIV-1 gene expression Alexander Zhyvoloup, Anat Melamed, Ian Anderson, Delphine Planas, Janos Kriston-Vizi, Robin Ketteler, Chen-Hsuin Lee, Andy Merritt, Petronela Ancuta, Charles Bangham, Ariberto Fassati O9 Characterisation of new RNA polymerase III and RNA polymerase II transcriptional promoters in the Bovine Leukemia Virus genome Anthony Rodari, Benoit Van Driessche, Mathilde Galais, Nadége Delacourt, Sylvain Fauquenoy, Caroline Vanhulle, Anna Kula, Arsène Burny, Olivier Rohr, Carine Van Lint O10 Tissue-specific dendritic cells differentially modulate latent HIV-1 reservoirs Thijs van Montfort, Renee van der Sluis, Dave Speijer, Ben Berkhout Session 4: RNA trafficking & packaging O11 A novel cis-acting element affecting HIV replication Bo Meng, Andrzej Rutkowski, Neil Berry, Lars Dölken, Andrew Lever O12 Tolerance of HIV’s late gene expression towards stepwise codon adaptation Thomas Schuster, Benedikt Asbach, Ralf Wagner Session 5: Assembly & release O13 Importance of the tax-inducible actin-bundling protein fascin for transmission of human T cell leukemia virus Type 1 (HTLV-1) Christine Gross, Veit Wiesmann, Martina Kalmer, Thomas Wittenberg, Jan Gettemans, Andrea K. Thoma-Kress O14 Lentiviral nef proteins antagonize TIM-mediated inhibition of viral release Minghua Li, Eric O. Freed, Shan-Lu Liu Session 6: Pathogenesis & evolution O15 SEVI and semen prolong the half-life of HIV-1 Janis Müller, Jan Münch O16 CD169+ macrophages mediate retrovirus trans-infection of permissive lymphocytes to establish infection in vivo Xaver Sewald, Pradeep Uchil, Mark Ladinsky, Jagadish Beloor, Ruoxi Pi, Christin Herrmann, Nasim Motamedi, Thomas Murooka, Michael Brehm, Dale Greiner, Thorsten Mempel, Pamela Bjorkman, Priti Kumar, Walther Mothes O17 Efficient replication of a vpu containing SIVagm construct in African Green Monkeys requires an HIV-1 nef gene Simone Joas, Erica Parrish, Clement Wesley Gnanadurai, Edina Lump, Christina M. Stürzel, Nicholas F. Parrish, Ulrike Sauermann, Katharina Töpfer, Tina Schultheiss, Steven Bosinger, Guido Silvestri, Cristian Apetrei, Nicholas Huot, Michaela Müller-Trutwin, Daniel Sauter, Beatrice H. Hahn, Christiane Stahl-Hennig, Frank Kirchhoff O18 Reprogramming initiates mobilization of endogenous mutagenic LINE-1, Alu and SVA retrotransposons in human induced pluripotent stem cells with consequences for host gene expression Gerald Schumann, Sabine Jung-Klawitter, Nina V. Fuchs, Kyle R. Upton, Martin Muñoz-Lopez, Ruchi Shukla, Jichang Wang, Marta Garcia-Canadas, Cesar Lopez-Ruiz, Daniel J. Gerhardt, Attila Sebe, Ivana Grabundzija, Patricia Gerdes, Sylvia Merkert, Andres Pulgarin, Anja Bock, Ulrike Held, Anett Witthuhn, Alexandra Haase, Ernst J. Wolvetang, Ulrich Martin, Zoltán Ivics, Zsuzsanna Izsvák, J. Garcia-Perez, Geoffrey J. Faulkner O19 NF-κB activation induces expression of human endogenous retrovirus and particle production Tara Hurst, Aris Katzourakis, Gkikas Magiorkinis Session 7a and b: Innate sensing & intrinsic immunity O20 Identification of the phosphatase acting on T592 in SAMHD1 during M/G1 transition Kerstin Schott, Rita Derua, Janna Seifried, Andreas Reuter, Heike Schmitz, Christiane Tondera, Alberto Brandariz-Nuñez, Felipe Diaz-Griffero, Veerle Janssens, Renate König O21 Vpx overcomes a SAMHD1-independent block to HIV reverse transcription that is specific to resting CD4 T cells Hanna-Mari Baldauf, Lena Stegmann, Sarah-Marie Schwarz, Maud Trotard, Margarethe Martin, Gina Lenzi, Manja Burggraf, Xiaoyu Pan, Oliver I. Fregoso, Efrem S. Lim, Libin Abraham, Elina Erikson, Laura Nguyen, Ina Ambiel, Frank Rutsch, Renate König, Baek Kim, Michael Emerman, Oliver T. Fackler, Oliver T. Keppler O22 The role of SAMHD1 in antiviral restriction and immune sensing in the mouse Sabine Wittmann, Rayk Behrendt, Bianca Volkmann, Kristin Eissmann, Thomas Gramberg O23 T cells expressing reduced restriction factors are preferentially infected in therapy naïve HIV-1 patients Sebastian Bolduan, Herwig Koppensteiner, Stefanie Regensburg, Ruth Brack-Werner, Rika Draenert, Michael Schindler O24 cGAS-mediated innate immunity spreads through HIV-1 env-induced membrane fusion sites from infected to uninfected primary HIV-1 target cells Aurélie Ducroux, Shuting Xu, Aparna Ponnurangam, Sergej Franz, Angelina Malassa, Ellen Ewald, Christine Goffinet O25 Perturbation of innate RNA and DNA sensing by human T cell leukemia virus type 1 oncoproteins Sin-Yee Fung, Ching-Ping Chan, Chun-Kit Yuen, Kin-Hang Kok, Chin-Ping Chan, Dong-Yan Jin O26 Induction and anti-viral activity of Interferon α subtypes in HIV-1 infection Ulf Dittmer O27 Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance Dorota Kmiec, Shilpa Iyer, Christina Stürzel, Daniel Sauter, Beatrice Hahn, Frank Kirchhoff O28 DNA repair protein Rad18 restricts HIV-1 and LINE-1 life cycle Yasuo Ariumi, Mariko Yasuda-Inoue, Koudai Kawano, Satoshi Tateishi, Priscilla Turelli O29 Natural mutations in IFITM3 allow escape from post-translational regulation and toggle antiviral specificity Alex Compton, Nicolas Roy, Françoise Porrot, Anne Billet, Nicoletta Casartelli, Jacob Yount, Chen Liang, Oliver Schwartz Session 8: Adaptive immunity & immune evasion O30 Observing evolution in HIV-1 infection: phylogenetics and mutant selection windows to infer the influence of the autologous antibody response on the viral quasispecies Carsten Magnus, Lucia Reh, Penny Moore, Therese Uhr, Jacqueline Weber, Lynn Morris, Alexandra Trkola O31 Dose and subtype specific analyses of the anti-HIV effects of IFN-alpha family members Rashel V. Grindberg, Erika Schlaepfer, Gideon Schreiber, Viviana Simon, Roberto F. Speck Session 9: Novel antiviral strategies O32 LEDGIN-mediated inhibition of the integrase-LEDGF/p75 interaction reduces reactivation of residual latent HIV Zeger Debyser, Lenard Vranckx, Jonas Demeulemeester, Suha Saleh, Eric Verdin, Anna Cereseto, Frauke Christ, Rik Gijsbers O33 NKG2D-mediated clearance of reactivated viral reservoirs by natural killer cells O34 Inhibition of HIV reactivation in brain cells by AAV-mediated delivery of CRISPR/Cas9 O35 CRISPR-Cas9 as antiviral: potent HIV-1 inhibition, but rapid virus escape and the subsequent design of escape-proof antiviral strategies Ben Berkhout, Gang Wang, Na Zhao, Atze T. Das Session 10: Recent advances in HIV vaccine development O36 Priming with a potent HIV-1 DNA vaccine frames the quality of T cell and antibody responses prior to a poxvirus and protein boost Benedikt Asbach, Josef Köstler, Beatriz Perdiguero, Mariano Esteban, Bertram L. Jacobs, David C. Montefiori, Celia C. LaBranche, Nicole L. Yates, Georgia D. Tomaras, Guido Ferrari, Kathryn E. Foulds, Mario Roederer, Gary Landucci, Donald N. Forthal, Michael S. Seaman, Natalie Hawkins, Steven G. Self, Sanjay Phogat, James Tartaglia, Susan W. Barnett, Brian Burke, Anthony D. Cristillo, Song Ding, Jonathan L. Heeney, Giuseppe Pantaleo, Ralf Wagner O37 Passive immunisation with a neutralising antibody against HIV-1 Env prevents infection of the first cells in a mucosal challenge rhesus monkey model Christiane Stahl-Hennig, Viktoria Stab, Armin Ensser, Ulrike Sauermann, Bettina Tippler, Dennis Burton, Matthias Tenbusch, Klaus Überla O38 HIV antibody Fc-glycoforms drive B cell affinity maturation Galit Alter, Giuseppe Lofano, Anne-Sophie Dugast, Viraj Kulkarni, Todd Suscovich Poster presentations Topic 1: Entry & uncoating P1 Dynein light chain is required for murine leukemia virus infection Tatiana Opazo, Felipe Barraza, Diego Herrera, Andrea Garces, Tomas Schwenke, Diego Tapia, Jorge Cancino, Gloria Arriagada P2 Peptide paratope mimics of the broadly neutralising HIV-1 antibody b12 Christina Haußner, Dominik Damm, Anette Rohrhofer, Barbara Schmidt, Jutta Eichler P3 Investigating cellular pathways involved in the transmission of HIV-1 between dendritic cells and T cells using RNAi screening techniques Rebecca Midgley, James Wheeldon, Vincent Piguet P4 Co-receptor tropism in HIV-1, HIV-2 monotypic and dual infections Priyanka Khopkar, Megha Rohamare, Smita Kulkarni P5 Characterisation of the role of CIB1 and CIB2 as HIV-1 helper factors Ana Godinho-Santos, Allan Hance, Joao Goncalves, Fabrizio Mammano P6 Buffering deleterious polymorphisms in the highly constrained C2 region of HIV-1 envelope by the flexible V3 domain Romain Gasser, Meriem Hamoudi, Martina Pellicciotta, Zhicheng Zhou, Clara Visdeloup, Philippe Colin, Martine Braibant, Bernard Lagane, Matteo Negroni P7 Entry inhibition of HERV-K(HML-2) by an Env-IgG fusion protein Jula Wamara, Norbert Bannert Topic 2: Reverse transcription & integration P8 The R263K/H51Y resistance substitutions in HIV integrase decreases levels of integrated HIV DNA over time Thibault Mesplede, Nathan Osman, Kaitlin Anstett, Jiaming Calvin Liang, Hanh Thi Pham, Mark Wainberg P9 The Retrovirus Integration Database (RID) Wei Shao, Jigui Shan, Mary Kearney, Xiaolin Wu, Frank Maldarelli, John Mellors, Brian Luke, John Coffin, Stephen Hughes P10 The small molecule 3G11 inhibits HIV-1 reverse transcription Thomas Fricke, Silvana Opp, Caitlin Shepard, Dmitri Ivanov, Baek Kim, Jose Valle-Casuso, Felipe Diaz-Griffero P11 Dual and opposite regulation of HIV-1 integration by hRAD51: impact on therapeutical approaches using homologous DNA repair modulators Vincent Parissi P12 A flexible motif essential for integration by HIV-1 integrase Marine Kanja, Pierre Cappy, Matteo Negroni, Daniela Lener P13 Interaction between HIV-1 integrase and the host protein Ku70: identification of the binding site and study of the influence on integrase-proteasome interplay Ekaterina Knyazhanskaya, Andrey Anisenko, Timofey Zatsepin, Marina Gottikh P14 Normalisation based method for deep sequencing of somatic retroelement integrations in human genome Alexander Komkov, Anastasia Minervina, Gaiaz Nugmanov, Vadim Nazarov, Konstantin Khodosevich, Ilgar Mamedov, Yuri Lebedev Topic 3: Transcription and latency P15 BCA2/RABRING7 restricts HIV-1 transcription by preventing the nuclear translocation of NF-κB Marta Colomer-Lluch, Ruth Serra-Moreno P16 MATR3 post-transcriptional regulation of HIV-1 transcription during latency Ambra Sarracino, Anna Kula, Lavina Gharu, Alexander Pasternak, Carine Van Lint, Alessandro Marcello P17 HIV-1 tat intersects the SUMO pathway to regulate HIV-1 promoter activity Ann Marie McCartin, Anurag Kulkarni, Valentin Le Douce, Virginie Gautier P18 Conservation in HIV-1 Vpr guides tertiary gRNA folding and alternative splicing Ann Baeyens, Evelien Naessens, Anouk Van Nuffel, Karin Weening, Anne-Marie Reilly, Eva Claeys, Wim Trypsteen, Linos Vandekerckhove, Sven Eyckerman, Kris Gevaert, Bruno Verhasselt P19 The majority of reactivatable latent HIV are genetically distinct Hoi Ping Mok, Nicholas Norton, Axel Fun, Jack Hirst, Mark Wills, Andrew Lever P20 Do mutations in the tat exonic splice enhancer contribute to HIV-1 latency? Nicholas Norton, Hoi Ping Mok, Jack Hirst, Andrew Lever P21 Culture-to-Ct: A fast and direct RT-qPCR HIV gene reactivation screening method using primary T cell culture Valentin Le Douce, Ann Marie McCartin, Virginie Gautier P22 A novel approach to define populations of early silenced proviruses Dalibor Miklik, Filip Senigl, Jiri Hejnar Topic 4: RNA trafficking & packaging P23 Functional analysis of the structure and conformation of HIV-1 genome RNA DIS Jun-ichi Sakuragi, Sayuri Sakuragi, Masaru Yokoyama, Tatsuo Shioda, Hironori Sato P24 Regulation of foamy viral env splicing controls gag and pol expression Jochen Bodem, Rebecca Moschall, Sarah Denk, Steffen Erkelenz, Christian Schenk, Heiner Schaal Topic 5: Assembly & release P25 Transfer of HTLV-1 p8 to target T cells depends on VASP: a novel interaction partner of p8 Norbert Donhauser, Ellen Socher, Sebastian Millen, Heinrich Sticht, Andrea K. Thoma-Kress P26 COL4A1 and COL4A2 are novel HTLV-1 tax targets with a putative role in virus transmission Christine Gross, Sebastian Millen, Melanie Mann, Klaus Überla, Andrea K. Thoma-Kress P27 The C terminus of foamy virus gag protein is required for particle formation, and virus budding: starting assembly at the C terminus? Guochao Wei, Matthew J. Betts, Yang Liu, Timo Kehl, Robert B. Russell, Martin Löchelt P28 Generation of an antigen-capture ELISA and analysis of Rec and Staufen-1 effects on HERV-K(HML-2) virus particle production Oliver Hohn, Saeed Mostafa, Kirsten Hanke, Stephen Norley, Norbert Bannert P29 Antagonism of BST-2/tetherin is a conserved function of primary HIV-2 Env glycoproteins Chia-Yen Chen, Masashi Shingai, Pedro Borrego, Nuno Taveira, Klaus Strebel P30 Mutations in the packaging signal region of the HIV-1 genome cause a late domain mutant phenotype Chris Hellmund, Bo Meng, Andrew Lever P31 p6 regulates membrane association of HIV-1 gag Melanie Friedrich, Friedrich Hahn, Christian Setz, Pia Rauch, Kirsten Fraedrich, Alina Matthaei, Petra Henklein, Maximilian Traxdorf, Torgils Fossen, Ulrich Schubert Topic 6: Pathogenesis & evolution P32 Molecular and structural basis of protein evolution during viral adaptation Aya Khwaja, Meytal Galilee, Akram Alian P33 HIV-1 enhancement and neutralisation by soluble gp120 and its role for the selection of the R5-tropic “best fit” Birco Schwalbe, Heiko Hauser, Michael Schreiber P34 An insertion of seven amino acids in the Env cytoplasmic tail of Human Immunodeficiency Virus type 2 (HIV-2) selected during disease progression enhances viral replication François Dufrasne, Mara Lucchetti, Patrick Goubau, Jean Ruelle P35 Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 T-cell count at 96 weeks ART Mirte Scherpenisse, Ben Berkhout, Alexander Pasternak P36 Faster progression in non-B subtype HIV-1-infected patients than Korean subclade of subtype B is accompanied by higher variation and no induction of gross deletion in non-B nef gene by Korean red ginseng treatment Young-Keol Cho, Jungeun Kim, Daeun Jeong P37 Aberrant expression of ERVWE1 endogenous retrovirus and overexpression of TET dioxygenases are characteristic features of seminoma Katerina Trejbalova, Martina Benesova, Dana Kucerova, Zdenka Vernerova, Rachel Amouroux, Petra Hajkova, Jiri Hejnar P38 Life history of the oldest lentivirus: characterisation of ELVgv integrations and the TRIM5 selection pattern in dermoptera Daniel Elleder, Tomas Hron, Helena Farkasova, Abinash Padhi, Jan Paces P39 Characterisation of a highly divergent endogenous retrovirus in the equine germ line Henan Zhu, Robert Gifford, Pablo Murcia P40 The emergence of pandemic retroviral infection in small ruminants Maria Luisa Carrozza, Anna-Maria Niewiadomska, Maurizio Mazzei, Mounir Abi-Said, Joseph Hughes, Stéphane Hué, Robert Gifford P41 Near full-length genome (NFLG) Characterisation of HIV-1 subtype B identified in South Africa Adetayo Obasa, Graeme Jacobs, Susan Engelbrecht P42 Acquisition of Vpu-mediated tetherin antagonism by an HIV-1 group O strain Katharina Mack, Kathrin Starz, Daniel Sauter, Matthias Geyer, Frederic Bibollet-Ruche, Christina Stürzel, Marie Leoz, Jean Christophe Plantier, Beatrice H. Hahn, Frank Kirchhoff P43 The human endogenous retrovirus type K is involved in cancer stem cell markers expression and in human melanoma malignancy Ayele Argaw-Denboba, Emanuela Balestrieri, Annalucia Serafino, Ilaria Bucci, Chiara Cipriani, Corrado Spadafora, Paolo Sinibaldi-Vallebona, Claudia Matteucci P44 Natural infection of Indian non-human primates by unique lentiviruses S. Nandi Jayashree, Ujjwal Neogi, Anil K. Chhangani, Shravan Sing Rathore, Bajrang R. J. Mathur P45 Free cervical cancer screening among HIV-positive women receiving antiretroviral treatment in Nigeria Adeyemi Abati P46 Molecular evolutionary status of feline immunodeficiency virus in Turkey B. Taylan Koç, Tuba Çiğdem Oğuzoğlu Topic 7: Innate sensing & intrinsic immunity P47 Cell-to-cell contact with HTLV-1-infected T cells reduces dendritic cell immune functions and contributes to infection in trans. Takatoshi Shimauchi, Stephan Caucheteux, Jocelyn Turpin, Katja Finsterbusch, Charles Bangham, Yoshiki Tokura, Vincent Piguet P48 Deciphering the mechanisms of HIV-1 exacerbation induced by Mycobacterium tuberculosis in monocytes/macrophages Shanti Souriant, Luciana Balboa, Karine Pingris, Denise Kviatcowsky, Brigitte Raynaud-Messina, Céline Cougoule, Ingrid Mercier, Marcelo Kuroda, Pablo González-Montaner, Sandra Inwentarz, Eduardo Jose Moraña, Maria del Carmen Sasiain, Olivier Neyrolles, Isabelle Maridonneau-Parini, Geanncarlo Lugo-Villarino, Christel Vérollet P49 The SAMHD1-mediated inhibition of LINE-1 retroelements is regulated by phosphorylation Alexandra Herrmann, Sabine Wittmann, Caitlin Shepard, Dominique Thomas, Nerea Ferreirós Bouzas, Baek Kim, Thomas Gramberg P50 Activities of nuclear envelope protein SUN2 in HIV infection Xavier Lahaye, Anvita Bhargava, Takeshi Satoh, Matteo Gentili, Silvia Cerboni, Aymeric Silvin, Cécile Conrad, Hakim Ahmed-Belkacem, Elisa C. Rodriguez, Jean-François Guichou, Nathalie Bosquet, Matthieu Piel, Roger Le Grand, Megan King, Jean-Michel Pawlotsky, Nicolas Manel P51 Activation of TLR7/8 with a small molecule agonist induces a novel restriction to HIV-1 infection of monocytes Henning Hofmann, Benedicte Vanwalscappel, Nicolin Bloch, Nathaniel Landau P52 Steady state between the DNA polymerase and Rnase H domain activities of reverse transcriptases determines the sensitivity of retroviruses to inhibition by APOBEC3 proteins Stanislav Indik, Benedikt Hagen P53 HIV restriction in mature dendritic cells is related to p21 induction and p21-mediated control of the dNTP pool and SAMHD1 activity. José Carlos Valle-Casuso, Awatef Allouch, Annie David, Françoise Barré-Sinoussi, Michaela Müller-Trutwin, Monsef Benkirane, Gianfranco Pancino, Asier Saez-Cirion P54 IFITM protens restrict HIV-1 protein synthesis Wing-Yiu Lee, Chen Liang, Richard Sloan P55 Characterisation and functional analysis of the novel restriction factor Serinc5 Bianca Schulte, Silvana Opp, Felipe Diaz-Griffero P56 piRNA sequences are common in Human Endogenous Retroviral Sequences (HERVs): An antiretroviral restriction mechanism? Jonas Blomberg, Luana Vargiu, Patricia Rodriguez-Tomé, Enzo Tramontano, Göran Sperber P57 Ferroportin restricts HIV-1 infection in sickle cell disease Namita Kumari, Tatiana Ammosova, Sharmeen Diaz, Patricia Oneal, Sergei Nekhai P58 APOBEC3G modulates the response to antiretroviral drugs in humanized mice Audrey Fahrny, Gustavo Gers-Huber, Annette Audigé, Roberto F. Speck, Anitha Jayaprakash, Ravi Sachidanandam, Matt Hernandez, Marsha Dillon-White, Viviana Simon P59 High-throughput epigenetic analysis of evolutionarily young endogenous retrovirus presents in the mule deer (Odocoileus hemionus) genome Tomas Hron, Helena Farkasova, Daniel Elleder P60 Characterisation of the expression of novel endogenous retroviruses and immune interactions in a macaque model Neil Berry, Emmanuel Maze, Claire Ham, Neil Almond, Greg Towers, Robert Belshaw P61 HIV-1 restriction by orthologs of SERINC3 and SERINC5 Patrícia de Sousa-Pereira, Joana Abrantes, Massimo Pizzato, Pedro J. Esteves, Oliver T. Fackler, Oliver T. Keppler, Hanna-Mari Baldauf P62 TRIM19/PML restricts HIV infection in a cell type-dependent manner Bianca Volkmann, Tanja Kahle, Kristin Eissmann, Alexandra Herrmann, Sven Schmitt, Sabine Wittmann, Laura Merkel, Nina Reuter, Thomas Stamminger, Thomas Gramberg P63 Recent invasion of the mule deer genome by a retrovirus Helena Farkasova, Tomas Hron, Daniel Elleder P64 Does the antiviral protein SAMHD1 influence mitochondrial function? Ilaria Dalla Rosa, Kate Bishop, Antonella Spinazzola, Harriet Groom P65 cGAMP transfers intercellularly via HIV-1 Env-mediated cell–cell fusion sites and triggers an innate immune response in primary target cells Shuting Xu, Aurélie Ducroux, Aparna Ponnurangam, Sergej Franz, Gabrielle Vieyres, Mathias Müsken, Thomas Zillinger, Angelina Malassa, Ellen Ewald, Veit Hornung, Winfried Barchet, Susanne Häussler, Thomas Pietschmann, Christine Goffinet P66 Pre-infection transcript levels of FAM26F in PBMCS inform about overall plasma viral load in acute and postacute phase after SIV-infection Ulrike Sauermann, Aneela Javed, Nicole Leuchte, Gabriela Salinas, Lennart Opitz, Christiane Stahl-Hennig, Sieghart Sopper P67 Sequence-function analysis of three T cell receptors targeting the HIV-1 p17 epitope SLYNTVATL Christiane Mummert, Christian Hofmann, Angela G. Hückelhoven, Silke Bergmann, Sandra M. Müller-Schmucker, Ellen G. Harrer, Jan Dörrie, Niels Schaft, Thomas Harrer P68 An immunodominant region of the envelope glycoprotein of small ruminant lentiviruses may function as decoy antigen Laure Cardinaux, M.-L. Zahno, H.-R. Vogt, R. Zanoni, G. Bertoni P69 Impact of immune activation, immune exhaustion, broadly neutralising antibodies and viral reservoirs on disease progression in HIV-infected children Maximilian Muenchhoff, Philip Goulder, Oliver Keppler Topic 9: Novel antiviral strategies P70 Identification of natural compounds as new antiviral products by bioassay-guided fractionation Alexandra Herrmann, Stephanie Rebensburg, Markus Helfer, Michael Schindler, Ruth Brack-Werner P71 The PPARG antagonism disconnects the HIV replication and effector functions in Th17 cells Yuwei Zhang, Huicheng Chen, Delphine Planas, Annie Bernier, Annie Gosselin, Jean-Pierre Routy, Petronela Ancuta P72 Characterisation of a multiresistant subtype AG reverse transcriptase: AZT resistance, sensitivity to RNase H inhibitors and inhibitor binding Birgitta Wöhrl, Anna Schneider, Angela Corona, Imke Spöring, Mareike Jordan, Bernd Buchholz, Elias Maccioni, Roberto Di Santo, Jochen Bodem, Enzo Tramontano, Kristian Schweimer P73 Insigths into the acetylation pattern of HDAC inhibitors and their potential role in HIV therapy Christian Schölz, Brian Weinert, Sebastian Wagner, Petra Beli, Yasuyuki Miyake, Jun Qi, Lars Jensen, Werner Streicher, Anna McCarthy, Nicholas Westwood, Sonia Lain, Jürgen Cox, Patrick Matthias, Matthias Mann, James Bradner, Chunaram Choudhary P74 HPV-derived and seminal amyloid peptides enhance HIV-1 infection and impair the efficacy of broadly neutralising antibodies and antiretroviral drugs Marcel Stern, Oliver T. Keppler P75 D(−)lentiginosine inhibits both proliferation and virus expression in cells infected by HTLV-1 in vitro Elena Valletta, Caterina Frezza, Claudia Matteucci, Francesca Marino-Merlo, Sandro Grelli, Anna Lucia Serafino, Antonio Mastino, Beatrice Macchi P76 HIV-1 resistance analyses of the Cape Winelands districts, South Africa Sello Mikasi, Graeme Jacobs, Susan Engelbrecht Topic 10: Recent advances in HIV vaccine development P77 Induction of complex retrovirus antigen-specific immune responses by adenovirus-based vectors depends on the order of vector administration Meike Kaulfuß, Sonja Windmann, Wibke Bayer P78 Direct impact of structural properties of HIV-1 Env on the regulation of the humoral immune response Rebecca Heß, Michael Storcksdieck gen. Bonsmann, Viktoria Stab, Carsten Kirschning, Bernd Lepenies, Matthias Tenbusch, Klaus Überla P79 Lentiviral virus-like particles mediate gerenration of T-follicular helper cells in vitro Anne Kolenbrander, Klaus Überla, Vladimir Temchura P80 Recruitment of HIV-1 Vpr to DNA damage sites and protection of proviral DNA from nuclease activity Kenta Iijima, Junya Kobayashi, Yukihito Ishizaka
- Published
- 2016
- Full Text
- View/download PDF
226. Synthesis and Evaluation of the Anti-HIV Activity of Aza and Deaza Analogs of IsoddA and Their Phosphates as Prodrugs
- Author
-
Franchetti, Palmarisa, primary, Cappellacci, Loredana, additional, Grifantini, Mario, additional, Messini, Lea, additional, Sheikha, Ghassan Abu, additional, Loi, Anna Giulia, additional, Tramontano, Enzo, additional, De Montis, Antonella, additional, Spiga, Maria Grazia, additional, and La Colla, Paolo, additional
- Published
- 1994
- Full Text
- View/download PDF
227. Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities.
- Author
-
Esposito, Francesca, Sanna, Cinzia, Del Vecchio, Claudia, Cannas, Valeria, Venditti, Alessandro, Corona, Angela, Bianco, Armandodoriano, Serrilli, Anna M., Guarcini, Laura, Parolin, Cristina, Ballero, Mauro, and Tramontano, Enzo
- Subjects
HYPERICUM ,ENZYME inhibitors ,REVERSE transcriptase ,HIV ,DNA polymerases ,RIBONUCLEASES ,VIRUS-induced enzymes - Abstract
Among HIV-1 reverse transcriptase ( RT)-associated functions, DNA polymerase and Ribonuclease H ( RNase H) are both essential for HIV replication and excellent targets for drug development. While all RT inhibitors approved for therapy target the DNA polymerase activity, there is the pressing need for new RT inhibitors possibly targeting the RNase H function. In the last 20 years, many natural substances have shown antiviral activity against HIV-1, but only a few against the RNase H function. In this study, we have tested the ethanolic extracts obtained by the Hypericum hircinum L. ( Hypericaceae) growing in Sardinia ( Italy) on the HIV-1 RT-associated RNase H function and found that they have inhibitory effects. Active extracts were fractionated up to obtain the main components that have been isolated, tested, and identified to be betulinic acid, shikimic acid, chlorogenic acid, quercetin, 5,7,3′,5′-tetrahydroxyflavanone, and 5,7,3′,5′-tetrahydroxyflavanone 7- O-glucoside. Betulinic acid and 5,7,3′,5′-tetrahydroxyflavanone 7- O-glucoside were active on both RT-associated activities, and betulinic acid was also active on HIV-1 mutant RTs resistant to efavirenz. Overall, our results suggest that some of these compounds inhibit the HIV-1 RT binding to an allosteric site previously described for other natural compounds and are potential leads for further drug development of a single molecules having dual inhibitory activity. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
228. Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate
- Author
-
Im, Guang-Jin, primary, Tramontano, Enzo, additional, Gonzalez, Charles J., additional, and Cheng, Yung-Chi, additional
- Published
- 1993
- Full Text
- View/download PDF
229. Anti-AIDS Agents, 6. Salaspermic Acid, an Anti-HIV Principle from Tripterycium wilfordii, and the Structure-activity Correlation with its Related Compounds
- Author
-
Chen, Ke, primary, Shi, Qian, additional, Kashiwada, Yoshiki, additional, Zhang, De-Cheng, additional, Hu, Chang-Qi, additional, Jin, Ji-Qin, additional, Nozaki, Hiroshi, additional, Kilkuskie, Robert E., additional, Tramontano, Enzo, additional, Cheng, Yung-Chi, additional, McPhail, Donald R., additional, McPhail, Andrew T., additional, and Lee, Kuo-Hsiung, additional
- Published
- 1992
- Full Text
- View/download PDF
230. Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides
- Author
-
Manfredini, Stefano, primary, Bazzanini, Rita, additional, Baraldi, Pier Giovanni, additional, Guarneri, Mario, additional, Simoni, Daniele, additional, Marongiu, Maria E., additional, Pani, Alessandra, additional, La Colla, Paolo, additional, and Tramontano, Enzo, additional
- Published
- 1992
- Full Text
- View/download PDF
231. Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.
- Author
-
Esposito, Francesca, Kharlamova, Tatyana, Distinto, Simona, Zinzula, Luca, Cheng, Yung-Chi, Dutschman, Ginger, Floris, Giovanni, Markt, Patrick, Corona, Angela, and Tramontano, Enzo
- Subjects
ENZYME inhibitors ,REVERSE transcriptase polymerase chain reaction ,DNA polymerases ,ENZYME activation ,HIV infections ,ANTI-HIV agents ,NUCLEOTIDE sequence ,RIBONUCLEASES ,VIRAL replication - Abstract
HIV-1 reverse transcriptase (RT) has two associated activities, DNA polymerase and RNase H, both essential for viral replication and validated drug targets. Although all RT inhibitors approved for therapy target DNA polymerase activity, the search for new RT inhibitors that target the RNase H function and are possibly active on RTs resistant to the known non-nucleoside inhibitors (NNRTI) is a viable approach for anti-HIV drug development. In this study, several alizarine derivatives were synthesized and tested for both HIV-1 RT-associated activities. Alizarine analogues K-49 and KNA-53 showed IC values for both RT-associated functions of ∼ 10 μ. When tested on the K103N RT, both derivatives inhibited the RT-associated functions equally, whereas when tested on the Y181C RT, KNA-53 inhibited the RNase H function and was inactive on the polymerase function. Mechanism of action studies showed that these derivatives do not intercalate into DNA and do not chelate the divalent cofactor Mg. Kinetic studies demonstrated that they are noncompetitive inhibitors, they do not bind to the RNase H active site or to the classical NNRTI binding pocket, even though efavirenz binding negatively influenced K-49/KNA-53 binding and vice versa. This behavior suggested that the alizarine derivatives binding site might be close to the NNRTI binding pocket. Docking experiments and molecular dynamic simulation confirmed the experimental data and the ability of these compounds to occupy a binding pocket close to the NNRTI site. Newly synthesized alizarine analogues inhibited both HIV-1 wild-type reverse transcriptase (RT)-associated DNA polymerase and RNase H functions, and retained their inhibitory effect also on the RT-associated RNase H function of K103N and Y181C RTs. Mechanism of action studies, docking experiments and molecular dynamic simulation showed that they are allosteric inhibitors and occupy a binding pocket close to the NNRTI site. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
232. INMI1 Zika Virus NS4B Antagonizes the Interferon Signaling by Suppressing STAT1 Phosphorylation.
- Author
-
Fanunza, Elisa, Grandi, Nicole, Quartu, Marina, Carletti, Fabrizio, Ermellino, Laura, Milia, Jessica, Corona, Angela, Capobianchi, Maria Rosaria, Ippolito, Giuseppe, and Tramontano, Enzo
- Subjects
ZIKA virus ,STAT proteins ,DENGUE viruses ,PHOSPHORYLATION ,GENE expression - Abstract
The evasion of the Interferon response has important implications in Zika virus (ZIKV) disease. Mutations in ZIKV viral protein NS4B, associated with modulation of the interferon (IFN) system, have been linked to increased pathogenicity in animal models. In this study, we unravel ZIKV NS4B as antagonist of the IFN signaling cascade. Firstly, we reported the genomic characterization of NS4B isolated from a strain of the 2016 outbreak, ZIKV Brazil/2016/INMI1, and we predicted its membrane topology. Secondly, we analyzed its phylogenetic correlation with other flaviviruses, finding a high similarity with dengue virus 2 (DEN2) strains; in particular, the highest conservation was found when NS4B was aligned with the IFN inhibitory domain of DEN2 NS4B. Hence, we asked whether ZIKV NS4B was also able to inhibit the IFN signaling cascade, as reported for DEN2 NS4B. Our results showed that ZIKV NS4B was able to strongly inhibit the IFN stimulated response element and the IFN-γ-activated site transcription, blocking IFN-I/-II responses. mRNA expression levels of the IFN stimulated genes ISG15 and OAS1 were also strongly reduced in presence of NS4B. We found that the viral protein was acting by suppressing the STAT1 phosphorylation and consequently blocking the nuclear transport of both STAT1 and STAT2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
233. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
- Author
-
Costanzi, Elisa, Kuzikov, Maria, Esposito, Francesca, Albani, Simone, Demitri, Nicola, Giabbai, Barbara, Camasta, Marianna, Tramontano, Enzo, Rossetti, Giulia, Zaliani, Andrea, and Storici, Paola
- Subjects
SARS-CoV-2 ,COVID-19 pandemic ,DRUG design ,SPACE groups ,COVALENT bonds - Abstract
After almost two years from its first evidence, the COVID-19 pandemic continues to afflict people worldwide, highlighting the need for multiple antiviral strategies. SARS-CoV-2 main protease (Mpro/3CLpro) is a recognized promising target for the development of effective drugs. Because single target inhibition might not be sufficient to block SARS-CoV-2 infection and replication, multi enzymatic-based therapies may provide a better strategy. Here we present a structural and biochemical characterization of the binding mode of MG-132 to both the main protease of SARS-CoV-2, and to the human Cathepsin-L, suggesting thus an interesting scaffold for the development of double-inhibitors. X-ray diffraction data show that MG-132 well fits into the Mpro active site, forming a covalent bond with Cys145 independently from reducing agents and crystallization conditions. Docking of MG-132 into Cathepsin-L well-matches with a covalent binding to the catalytic cysteine. Accordingly, MG-132 inhibits Cathepsin-L with nanomolar potency and reversibly inhibits Mpro with micromolar potency, but with a prolonged residency time. We compared the apo and MG-132-inhibited structures of Mpro solved in different space groups and we identified a new apo structure that features several similarities with the inhibited ones, offering interesting perspectives for future drug design and in silico efforts. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
234. In Vitro Anti-HIV-1 Reverse Transcriptase and Integrase Properties of Punica granatum L. Leaves, Bark, and Peel Extracts and Their Main Compounds.
- Author
-
Sanna, Cinzia, Marengo, Arianna, Acquadro, Stefano, Caredda, Alessia, Lai, Roberta, Corona, Angela, Tramontano, Enzo, Rubiolo, Patrizia, and Esposito, Francesca
- Subjects
REVERSE transcriptase ,TANNINS ,RIBONUCLEASE H ,POMEGRANATE ,BETULINIC acid ,ELLAGIC acid ,URSOLIC acid - Abstract
In a search for natural compounds with anti-HIV-1 activity, we studied the effect of the ethanolic extract obtained from leaves, bark, and peels of Punica granatum L. for the inhibition of the HIV-1 reverse transcriptase (RT)-associated ribonuclease H (RNase H) and integrase (IN) LEDGF-dependent activities. The chemical analyses led to the detection of compounds belonging mainly to the phenolic and flavonoid chemical classes. Ellagic acid, flavones, and triterpenoid molecules were identified in leaves. The bark and peels were characterized by the presence of hydrolyzable tannins, such as punicalins and punicalagins, together with ellagic acid. Among the isolated compounds, the hydrolyzable tannins and ellagic acid showed a very high inhibition (IC
50 values ranging from 0.12 to 1.4 µM and 0.065 to 0.09 µM of the RNase H and IN activities, respectively). Of the flavonoids, luteolin and apigenin were found to be able to inhibit RNase H and IN functions (IC50 values in the 3.7–22 μM range), whereas luteolin 7-O-glucoside showed selective activity for HIV-1 IN. In contrast, betulinic acid, ursolic acid, and oleanolic acid were selective for the HIV-1 RNase H activity. Our results strongly support the potential of non-edible P. granatum organs as a valuable source of anti-HIV-1 compounds. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
235. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro
- Author
-
Tramontano, Enzo, Esposito, Francesca, Badas, Roberta, Di Santo, Roberto, Costi, Roberta, and La Colla, Paolo
- Subjects
- *
IMMUNODEFICIENCY , *NUCLEIC acids , *HIV , *REVERSE transcriptase - Abstract
Abstract: The human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase (RT) is a multifunctional enzyme which displays DNA polymerase activity, which recognizes RNA and DNA templates, and a degradative ribonuclease H (RNase H) activity. While both RT functions are required for retroviral replication, until now only the polymerase function has been widely explored as drug target. We have identified a novel diketo acid derivative, 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester (RDS 1643), which inhibits in enzyme assays the HIV-1 RT-associated polymerase-independent RNase H activity but has no effect on the HIV-1 RT-associated RNA-dependent DNA polymerase (RDDP) activity and on the RNase H activities displayed by the Avian Myeloblastosis Virus and E. coli. Time-dependence studies revealed that the compound is active independently on the order of its addition to the reaction mixture, and inhibition kinetics studies demonstrated that RDS 1643 inhibits the RNase H activity noncompetitively, with a KI value of 17μM. When RDS 1643 was combined with non-nucleoside RT inhibitors (NNRTI), such as efavirenz and nevirapine, results indicated that RDS 1643 does not affect the NNRTIs anti-RDDP activity and that, vice versa, the NNRTIs do not alter the RNase H inhibition by RDS 1643. When assayed on the viral replication in cell-based assays, RDS 1643 inhibited the HIV-1IIIB strain with an EC50 of 14μM. Similar results were obtained against the Y181C and Y181C/K103N HIV-1 NNRTI resistant mutant strains. RDS 1643 may be the first HIV-1 inhibitor selectively targeted to the viral RT-associated RNase-H function. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
236. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3′-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors
- Author
-
Tramontano, Enzo, Onidi, Loredana, Esposito, Francesca, Badas, Roberta, and La Colla, Paolo
- Subjects
- *
HIV , *DNA , *CATALYSIS , *CELL culture - Abstract
Human Immunodeficiency Virus type 1 (HIV-1) integrase (IN) is an attractive target for the development of new antiviral therapies. Recently, several HIV-1 recombinant IN (rIN) in vitro inhibitors have been described. However, the great majority of them failed to block the virus replication in cell-based assays, suggesting the inadequacy of the in vitro assay systems used for inhibitor screening. To improve these systems, we designed a 40mer duplex DNA reaction substrate consisting of recognition sequences from both U3 and U5 HIV-1 long terminal repeat (LTR) termini. The HIV-1 rIN was able to catalyze its enzyme activities recognizing both ends of the 40mer dsDNA. Using this substrate we assayed the effects on rIN catalysis of different classes of compounds which inhibit the HIV-1 rIN in vitro when the reaction substrate is the standard 21mer U5 dsDNA, and that are either active or inactive on the HIV-1 replication. We also compared the efficacy of these compounds when added to the reaction before or after the formation of the rIN–dsDNA complex. In this system, the enzyme preincubation with the two-ended 40mer dsDNA before the addition of the compounds allowed a strong correlation between the effects of hydroxylated aromatics derivatives on rIN activity in cell-free assays and their effects on viral replication in cell-culture assays. This increase in drug selectivity of the rIN in vitro assay was explored by investigating whether it was due to the length of the 40mer, longer than the standard 21mer, or to presence of both viral ends, versus only one viral end. To this purpose we designed four 40mer oligonucleotides containing either only one viral end or two-repetitive ends, finding that the architecture of the rIN–dsDNA complex and its compound susceptibility is significantly influenced by the sequence of the dsDNA substrate. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
237. The Methanolic Extract of Perilla frutescens Robustly Restricts Ebola Virus Glycoprotein-Mediated Entry.
- Author
-
Kuo, Yu-Ting, Liu, Ching-Hsuan, Corona, Angela, Fanunza, Elisa, Tramontano, Enzo, and Lin, Liang-Tzung
- Subjects
PERILLA frutescens ,EBOLA virus ,HEMORRHAGIC fever ,ANTIVIRAL agents ,EXTRACTS - Abstract
Ebola virus (EBOV), one of the most infectious human viruses and a leading cause of viral hemorrhagic fever, imposes a potential public health threat with several recent outbreaks. Despite the difficulties associated with working with this pathogen in biosafety level-4 containment, a protective vaccine and antiviral therapeutic were recently approved. However, the high mortality rate of EBOV infection underscores the necessity to continuously identify novel antiviral strategies to help expand the scope of prophylaxis/therapeutic management against future outbreaks. This includes identifying antiviral agents that target EBOV entry, which could improve the management of EBOV infection. Herein, using EBOV glycoprotein (GP)-pseudotyped particles, we screened a panel of natural medicinal extracts, and identified the methanolic extract of Perilla frutescens (PFME) as a robust inhibitor of EBOV entry. We show that PFME dose-dependently impeded EBOV GP-mediated infection at non-cytotoxic concentrations, and exerted the most significant antiviral activity when both the extract and the pseudoparticles are concurrently present on the host cells. Specifically, we demonstrate that PFME could block viral attachment and neutralize the cell-free viral particles. Our results, therefore, identified PFME as a potent inhibitor of EBOV entry, which merits further evaluation for development as a therapeutic strategy against EBOV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
238. Chemical Characterization and Anti-HIV-1 Activity Assessment of Iridoids and Flavonols from Scrophularia trifoliata.
- Author
-
Guzzo, Francesca, Russo, Rosita, Sanna, Cinzia, Celaj, Odeta, Caredda, Alessia, Corona, Angela, Tramontano, Enzo, Fiorentino, Antonio, Esposito, Francesca, and D'Abrosca, Brigida
- Subjects
FLAVONOLS ,RIBONUCLEASE H ,IRIDOIDS ,PLANT metabolites ,HIV ,ANTIVIRAL agents - Abstract
Plants are the everlasting source of a wide spectrum of specialized metabolites, characterized by wide variability in term of chemical structures and different biological properties such antiviral activity. In the search for novel antiviral agents against Human Immunodeficiency Virus type 1 (HIV-1) from plants, the phytochemical investigation of Scrophularia trifoliata L. led us to isolate and characterize four flavonols glycosides along with nine iridoid glycosides, two of them, 5 and 13, described for the first time. In the present study, we investigated, for the first time, the contents of a methanol extract of S. trifoliata leaves, in order to explore the potential antiviral activity against HIV-1. The antiviral activity was evaluated in biochemical assays for the inhibition of HIV-1Reverse Transcriptase (RT)-associated Ribonuclease H (RNase H) activity and HIV-1 Integrase (IN). Three isolated flavonoids, rutin, kaempferol-7-O-rhamnosyl-3-O-glucopyranoside, and kaempferol-3-O-glucopyranoside, 8–10, inhibited specifically the HIV-1 IN activity at submicromolar concentration, with the latter being the most potent, showing an IC
50 value of 24 nM. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
239. Exploring New Scaffolds for the Dual Inhibition of HIV-1 RT Polymerase and Ribonuclease Associated Functions.
- Author
-
Meleddu, Rita, Corona, Angela, Distinto, Simona, Cottiglia, Filippo, Deplano, Serenella, Sequeira, Lisa, Secci, Daniela, Onali, Alessia, Sanna, Erica, Esposito, Francesca, Cirone, Italo, Ortuso, Francesco, Alcaro, Stefano, Tramontano, Enzo, Mátyus, Péter, and Maccioni, Elias
- Subjects
HIV ,RIBONUCLEASES ,REVERSE transcriptase ,HIV infections ,ANTIRETROVIRAL agents ,PATIENT compliance - Abstract
Current therapeutic protocols for the treatment of HIV infection consist of the combination of diverse anti-retroviral drugs in order to reduce the selection of resistant mutants and to allow for the use of lower doses of each single agent to reduce toxicity. However, avoiding drugs interactions and patient compliance are issues not fully accomplished so far. Pursuing on our investigation on potential anti HIV multi-target agents we have designed and synthesized a small library of biphenylhydrazo 4-arylthiazoles derivatives and evaluated to investigate the ability of the new derivatives to simultaneously inhibit both associated functions of HIV reverse transcriptase. All compounds were active towards the two functions, although at different concentrations. The substitution pattern on the biphenyl moiety appears relevant to determine the activity. In particular, compound 2-{3-[(2-{4-[4-(hydroxynitroso)phenyl]-1,3-thiazol-2-yl} hydrazin-1-ylidene) methyl]-4-methoxyphenyl} benzamide bromide (EMAC2063) was the most potent towards RNaseH (IC
50 = 4.5 mM)- and RDDP (IC50 = 8.0 mM) HIV RT-associated functions. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
240. HERV-K(HML7) Integrations in the Human Genome: Comprehensive Characterization and Comparative Analysis in Non-Human Primates.
- Author
-
Grandi, Nicole, Pisano, Maria Paola, Pessiu, Eleonora, Scognamiglio, Sante, Tramontano, Enzo, and Riley, David G.
- Subjects
HUMAN endogenous retroviruses ,NON-coding DNA ,PRIMATES ,ENDOGENOUS retroviruses ,X chromosome ,HUMAN chromosomes ,HUMAN genome - Abstract
Simple Summary: The human genome is not human at all, but it includes a multitude of sequences inherited from ancient viral infections that affected primates' germ line. These elements can be seen as the fossils of now-extinct retroviruses, and are called Human Endogenous Retroviruses (HERVs). View as "junk DNA" for a long time, HERVs constitute 4 times the amount of DNA needed to produce all cellular proteins, and growing evidence indicates their crucial role in primate brain evolution, placenta development, and innate immunity shaping. HERVs are also intensively studied for a pathological role, even if the incomplete knowledge about their exact number and genomic position has thus far prevented any causal association. Among possible relevant HERVs, the HERV-K supergroup is of particular interest, including some of the oldest (HML5) as well as youngest (HML2) integrations. Among HERV-Ks, the HML7 group still lack a detailed description, and the present work thus aimed to identify and characterize all HML7 elements in the human genome. Results showed that the HML7 group includes 23 elements and an additional 160 "scars" of past infection that invaded in primates mostly between 20 and 30 million years ago, providing an exhaustive background to study their impact on human pathophysiology. Endogenous Retroviruses (ERVs) are ancient relics of infections that affected the primate germ line and constitute about 8% of our genome. Growing evidence indicates that ERVs had a major role in vertebrate evolution, being occasionally domesticated by the host physiology. In addition, human ERV (HERV) expression is highly investigated for a possible pathological role, even if no clear associations have been reported yet. In fact, on the one side, the study of HERV expression in high-throughput data is a powerful and promising tool to assess their actual dysregulation in diseased conditions; but, on the other side, the poor knowledge about the various HERV group genomic diversity and individual members somehow prevented the association between specific HERV loci and a given molecular mechanism of pathogenesis. The present study is focused on the HERV-K(HML7) group that—differently from the other HERV-K members—still remains poorly characterized. Starting from an initial identification performed with the software RetroTector, we collected 23 HML7 proviral insertions and about 160 HML7 solitary LTRs that were analyzed in terms of genomic distribution, revealing a significant enrichment in chromosome X and the frequent localization within human gene introns as well as in pericentromeric and centromeric regions. Phylogenetic analyses showed that HML7 members form a monophyletic group, which based on age estimation and comparative localization in non-human primates had its major diffusion between 20 and 30 million years ago. Structural characterization revealed that besides 3 complete HML7 proviruses, the other group members shared a highly defective structure that, however, still presents recognizable functional domains, making it worth further investigation in the human population to assess the presence of residual coding potential. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
241. Human Endogenous Retroviruses (HERVs) and Mammalian Apparent LTRs Retrotransposons (MaLRs) Are Dynamically Modulated in Different Stages of Immunity.
- Author
-
Pisano, Maria Paola, Grandi, Nicole, Tramontano, Enzo, and Drummer, Heidi
- Subjects
HUMAN endogenous retroviruses ,RETROTRANSPOSONS ,RETROVIRUS diseases ,VACCINE effectiveness ,IMMUNITY ,HEMORRHAGIC fever - Abstract
Simple Summary: Human Endogenous retroviruses (HERVs) and Mammalian Apparent LTRs Retrotransposons (MaLRs) are remnants of ancient retroviral infections that make up about 8% of the human genome. HERV and MaLR expression is regulated in immunity, and, in particular, is known for their up-regulation after innate immune activation. In this work, we analyzed the differential expression of HERVs and MaLRs in different stages of immunity, triggered by the administration of an inactivated vaccine. Human Endogenous retroviruses (HERVs) and Mammalian Apparent LTRs Retrotransposons (MaLRs) are remnants of ancient retroviral infections that represent a large fraction of our genome. The HERV and MaLR transcriptional activity is regulated in developmental stages, adult tissues, and pathological conditions. In this work, we used a bioinformatics approach based on RNA-sequencing (RNA-seq) to study the expression and modulation of HERVs and MaLR in a scenario of activation of the immune response. We analyzed transcriptome data from subjects before and after the administration of an inactivated vaccine against the Hantaan orthohantavirus, the causative agent of Korean hemorrhagic fever, to investigate the HERV and MaLR expression and differential expression in response to the administration of the vaccine. Specifically, we described the HERV transcriptome in PBMCs and identified HERV and MaLR loci differentially expressed after the 2nd, 3rd, and 4th inactivated vaccine administrations. We found that the expression of 545 HERV and MaLR elements increased in response to the vaccine and that the activation of several individual HERV and MaLR loci is specific for each vaccine administration and correlated to different genes and immune-related pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
242. Retrotransposons as Drivers of Mammalian Brain Evolution.
- Author
-
Ferrari, Roberto, Grandi, Nicole, Tramontano, Enzo, Dieci, Giorgio, Biscotti, Maria Assunta, and Canapa, Adriana
- Subjects
RETROTRANSPOSONS ,BIOLOGICAL fitness ,HOMINIDS ,GENETIC regulation ,NEOCORTEX - Abstract
Retrotransposons, a large and diverse class of transposable elements that are still active in humans, represent a remarkable force of genomic innovation underlying mammalian evolution. Among the features distinguishing mammals from all other vertebrates, the presence of a neocortex with a peculiar neuronal organization, composition and connectivity is perhaps the one that, by affecting the cognitive abilities of mammals, contributed mostly to their evolutionary success. Among mammals, hominids and especially humans display an extraordinarily expanded cortical volume, an enrichment of the repertoire of neural cell types and more elaborate patterns of neuronal connectivity. Retrotransposon-derived sequences have recently been implicated in multiple layers of gene regulation in the brain, from transcriptional and post-transcriptional control to both local and large-scale three-dimensional chromatin organization. Accordingly, an increasing variety of neurodevelopmental and neurodegenerative conditions are being recognized to be associated with retrotransposon dysregulation. We review here a large body of recent studies lending support to the idea that retrotransposon-dependent evolutionary novelties were crucial for the emergence of mammalian, primate and human peculiarities of brain morphology and function. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
243. Preliminary Evaluation of Protective Efficacy of Inactivated Senecavirus A on Pigs.
- Author
-
Li, Yuwan, Zhang, Yangyi, Liao, Yingxin, Sun, Yawei, Ruan, Yang, Liu, Chenchen, Zhang, Mengru, Li, Fangfang, Li, Xiaowen, Fan, Shuangqi, Yi, Lin, Ding, Hongxing, Zhao, Mingqiu, Fan, Jindai, Chen, Jinding, and Tramontano, Enzo
- Subjects
SWINE ,VIRAL shedding ,PIGLETS ,NEONATAL death ,VACCINATION ,SWINE breeding ,INFECTION control ,SYMPTOMS - Abstract
Senecavirus A (SVA), formerly known as Seneca Valley virus (SVV), causes vesicular symptoms in adult pigs and acute death of neonatal piglets. This pathogen has emerged in major swine producing countries around the world and caused significant economic losses to the pig industry. Thus, it is necessary to develop strategies to prevent and control SVA infection. Herein, an SVA strain (named GD-ZYY02-2018) was isolated from a pig herd with vesicular symptoms in Guangdong province of China in 2018. The present study aimed to carry out the phylogenetic analysis of the GD-ZYY02-2018 strain, determine its pathogenicity in finishing pigs, and assess the protective efficacy of the inactivated GD-ZYY02-2018 strain against virus challenge. The results of phylogenetic analysis showed that the SVA GD-ZYY02-2018 strain belonged to the USA-like strains and had a close genetic relationship with recent Chinese SVA strains. Animal challenge experiment showed that 100-day-old pigs inoculated intranasally with SVA GD-ZYY02-2018 strain developed vesicular lesion, low fever, viremia, and virus shedding in feces. The immunization challenge experiment showed that pigs vaccinated with inactivated GD-ZYY02-2018 strain could produce a high titer of anti-SVA neutralizing antibody and no vesicular lesion, fever, viremia, and virus shedding in feces was observed in vaccinated pigs after challenge with GD-ZYY02-2018 strain, indicating that inactivated GD-ZYY02-2018 could protect finishing pigs against the challenge of homologous virus. In conclusion, preliminary results indicated that inactivated GD-ZYY02-2018 could be used as a candidate vaccine for in-depth research and might be conducive to the prevention and control of SVA infection. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
244. Natural and Nature-Derived Products Targeting Human Coronaviruses.
- Author
-
Vougogiannopoulou, Konstantina, Corona, Angela, Tramontano, Enzo, Alexis, Michael N., Skaltsounis, Alexios-Leandros, and Habtemariam, Solomon
- Subjects
CORONAVIRUSES ,NATURAL products ,COVID-19 ,ANTIVIRAL agents ,SARS-CoV-2 ,SARS virus ,MERS coronavirus - Abstract
The ongoing pandemic of severe acute respiratory syndrome (SARS), caused by the SARS-CoV-2 human coronavirus (HCoV), has brought the international scientific community before a state of emergency that needs to be addressed with intensive research for the discovery of pharmacological agents with antiviral activity. Potential antiviral natural products (NPs) have been discovered from plants of the global biodiversity, including extracts, compounds and categories of compounds with activity against several viruses of the respiratory tract such as HCoVs. However, the scarcity of natural products (NPs) and small-molecules (SMs) used as antiviral agents, especially for HCoVs, is notable. This is a review of 203 publications, which were selected using PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar, evaluates the available literature since the discovery of the first human coronavirus in the 1960s; it summarizes important aspects of structure, function, and therapeutic targeting of HCoVs as well as NPs (19 total plant extracts and 204 isolated or semi-synthesized pure compounds) with anti-HCoV activity targeting viral and non-viral proteins, while focusing on the advances on the discovery of NPs with anti-SARS-CoV-2 activity, and providing a critical perspective. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
245. Probing the Importance of the G-Quadruplex Grooves for the Activity of the Anti-HIV-Integrase Aptamer T30923.
- Author
-
Esposito, Veronica, Esposito, Francesca, Pepe, Antonietta, Gomez Monterrey, Isabel, Tramontano, Enzo, Mayol, Luciano, Virgilio, Antonella, and Galeone, Aldo
- Subjects
APTAMERS ,METHYL groups ,CIRCULAR dichroism ,MOLECULAR models ,DATA modeling - Abstract
In this paper, we report studies concerning four variants of the G-quadruplex forming anti-HIV-integrase aptamer T30923, in which specific 2′-deoxyguanosines have been singly replaced by 8-methyl-2′-deoxyguanosine residues, with the aim to exploit the methyl group positioned in the G-quadruplex grooves as a steric probe to investigate the interaction aptamer/target. Although, the various modified aptamers differ in the localization of the methyl group, NMR, circular dichroism (CD), electrophoretic and molecular modeling data suggest that all of them preserve the ability to fold in a stable dimeric parallel G-quadruplex complex resembling that of their natural counterpart T30923. However, the biological data have shown that the T30923 variants are characterized by different efficiencies in inhibiting the HIV-integrase, thus suggesting the involvement of the G-quadruplex grooves in the aptamer/target interaction. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
246. Contribution of Human Retroviruses to Disease Development—A Focus on the HIV– and HERV–Cancer Relationships and Treatment Strategies.
- Author
-
Liu, Ching-Hsuan, Grandi, Nicole, Palanivelu, Lalitha, Tramontano, Enzo, and Lin, Liang-Tzung
- Subjects
RETROVIRUSES ,HTLV ,AIDS ,RETROVIRUS diseases ,HUMAN endogenous retroviruses ,KAPOSI'S sarcoma ,ANTIRETROVIRAL agents - Abstract
Animal retroviruses are known for their transforming potential, and this is also true for the ones hosted by humans, which have gathered expanding attention as one of the potent causative agents in various disease, including specific cancer types. For instance, Human T Lymphotropic virus (HTLV) is a well-studied class of oncoviruses causing T cell leukemia, while human immunodeficiency virus (HIV) leads to acquired immunodeficiency syndrome (AIDS), which is linked to a series of defining cancers including Kaposi sarcoma, certain types of non-Hodgkin lymphoma, and cervical cancer. Of note, in addition to these "modern" exogenous retroviruses, our genome harbors a staggering number of human endogenous retroviruses (HERVs). HERVs are the genetic remnants of ancient retroviral germline infection of human ancestors and are typically silenced in normal tissues due to inactivating mutations and sequence loss. While some HERV elements have been appropriated and contribute to human physiological functions, others can be reactivated through epigenetic dysregulations to express retroviral elements and promote carcinogenesis. Conversely, HERV replication intermediates or protein products can also serve as intrinsic pathogen-associated molecular patterns that cause the immune system to interpret it as an exogenous infection, thereby stimulating immune responses against tumors. As such, HERVs have also been targeted as a potential internal strategy to sensitize tumor cells for promising immunotherapies. In this review, we discuss the dynamic role of human retroviruses in cancer development, focusing on HIV and HERVs contribution. We also describe potential treatment strategies, including immunotherapeutic targeting of HERVs, inhibiting DNA methylation to expose HERV signatures, and the use of antiretroviral drugs against HIV and HERVs, which can be employed as prospective anti-cancer modalities. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
247. Targeting HIV-1 RNase H: N'-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants.
- Author
-
Corona, Angela, Ballana, Ester, Distinto, Simona, Rogolino, Dominga, Del Vecchio, Claudia, Carcelli, Mauro, Badia, Roger, Riveira-Muñoz, Eva, Esposito, Francesca, Parolin, Cristina, Esté, José A., Grandi, Nicole, and Tramontano, Enzo
- Subjects
RIBONUCLEASE H ,REVERSE transcriptase ,SITE-specific mutagenesis ,VIRAL replication ,AMINO acids - Abstract
HIV-1 infection requires life-long treatment and with 2.1 million new infections/year, faces the challenge of an increased rate of transmitted drug-resistant mutations. Therefore, a constant and timely effort is needed to identify new HIV-1 inhibitors active against drug-resistant variants. The ribonuclease H (RNase H) activity of HIV-1 reverse transcriptase (RT) is a very promising target, but to date, still lacks an efficient inhibitor. Here, we characterize the mode of action of N'-(2-hydroxy-benzylidene)-3,4,5-trihydroxybenzoylhydrazone (compound 13), an N-acylhydrazone derivative that inhibited viral replication (EC
50 = 10 µM), while retaining full potency against the NNRTI-resistant double mutant K103N-Y181C virus. Time-of-addition and biochemical assays showed that compound 13 targeted the reverse-transcription step in cell-based assays and inhibited the RT-associated RNase H function, being >20-fold less potent against the RT polymerase activity. Docking calculations revealed that compound 13 binds within the RNase H domain in a position different from other selective RNase H inhibitors; site-directed mutagenesis studies revealed interactions with conserved amino acid within the RNase H domain, suggesting that compound 13 can be taken as starting point to generate a new series of more potent RNase H selective inhibitors active against circulating drug-resistant variants. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
248. High-Throughput Sequencing is a Crucial Tool to Investigate the Contribution of Human Endogenous Retroviruses (HERVs) to Human Biology and Development.
- Author
-
Pisano, Maria Paola, Grandi, Nicole, and Tramontano, Enzo
- Abstract
Human Endogenous retroviruses (HERVs) are remnants of ancient retroviral infections that represent a large fraction of our genome. Their transcriptional activity is finely regulated in early developmental stages and their expression is modulated in different cell types and tissues. Such activity has an impact on human physiology and pathology that is only partially understood up to date. Novel high-throughput sequencing tools have recently allowed for a great advancement in elucidating the various HERV expression patterns in different tissues as well as the mechanisms controlling their transcription, and overall, have helped in gaining better insights in an all-inclusive understanding of the impact of HERVs in biology of the host. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
249. Comprehensive Analysis of HERV Transcriptome in HIV+ Cells: Absence of HML2 Activation and General Downregulation of Individual HERV Loci.
- Author
-
Grandi, Nicole, Pisano, Maria Paola, Scognamiglio, Sante, Pessiu, Eleonora, and Tramontano, Enzo
- Subjects
HIV infections ,DOWNREGULATION ,CELL culture ,ANTIRETROVIRAL agents ,T cells ,HIV - Abstract
Human endogenous retrovirus (HERV) expression is currently studied for its possible activation by HIV infection. In this context, the HERV-K(HML2) group is the most investigated: it has been proposed that HIV-1 infection can prompt HML2 transcription, and that HML2 proteins can affect HIV-1 replication, either complementing HIV or possibly influencing antiretroviral therapy. However, little information is available on the expression of other HERV groups in HIV infection. In the present study, we used a bioinformatics pipeline to investigate the transcriptional modulation of approximately 3250 well-characterized HERV loci, comparing their expression in a public RNA-seq profile, including a HIV-1-infected and a control T cell culture. In our pilot study, we found approximately 200 HERV loci belonging to 35 HERV groups that were expressed in one or both conditions, with transcripts per million (TPM) values from 1 to >500. Intriguingly, HML2 elements constituted only the 3% of expressed HERV loci, and in most cases (160) HERV expression was downregulated in the HIV-infected culture, showing from a 1- to 14-fold decrease as compared to uninfected cells. HERV transcriptome has been inferred de novo and employed to predict a total of about 950 HERV open reading frames (ORFs). These have been validated according to the coding potential and estimated abundance of the corresponding transcripts, leading to a set of 57 putative proteins potentially encoded by 23 HERV loci. Analysis showed that some individual loci have a coding potential that deserves further investigation. Among them, a HML6 provirus at locus 19q13.43 was predicted to produce a transcript showing the highest TPM among HERV-derived transcripts, being upregulated in HIV+ cells and inferred to produce Gag and Env puteins with possible biological activity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
250. 2-(Arylamino)-6-(trifluoromethyl)nicotinic Acid Derivatives: New HIV-1 RT Dual Inhibitors Active on Viral Replication.
- Author
-
Corona, Angela, Onnis, Valentina, Del Vecchio, Claudia, Esposito, Francesca, Cheng, Yung-Chi, and Tramontano, Enzo
- Subjects
NIACIN ,REVERSE transcriptase ,RIBONUCLEASE H ,ACID derivatives ,VIRAL replication ,NICOTINAMIDE ,HERBICIDE resistance - Abstract
The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC
50 of 14 µM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.